Press and Investors Relations

Public Relations

We are always open to dialogue. As an industry expert, for scientific assessments, market analyzes – or simply to inform about us.

Public Affairs

Political decisions rely on facts and professional assessments. We are happy to be available as a partner and establish contact with recognized experts.

Regulators

The trusting cooperation with authorities is the basis of our activities. We are always available for questions.

Press Contact

Marcus Ewald
(+49) 176 22 82 42 18
marcus.ewald@farmako.de

Branding Assets

Here you can find all our branding assets like logotypes as well as pictures of our team and individual members.

Logotypes – Logotypes
Our Team – Team Pictures
Sebastian Diemer – Sebastian Diemer
Niklas Kouparanis – Niklas Kouparanis
Patrick Schmitt – Patrick Schmitt
Prof. Dr. Bernhard Lieb –  Prof. Dr. Bernhard Lieb
Dr. med. Lena Müller –  Dr. med. Lena Müller

Company Presentation

Here you can find our Company Presentation

Company Presentation – Company Presentation

Press releases

To view our press releases, please click the link below

View our Press Releases:

Press Release 20.03.2019

Press Release 11.12.2018
Press Release 17.12.2018
Press Release 09.01.2019

 

 

Farmako helps Canadian partners to obtain a EU-GMP certification.

Farmako is a rapidly growing company. We will become the gateway to all European markets that provide a legal basis for pharmaceutical cannabis. Our explicit goal is to be the first company to obtain a respective licence in any newly opening European market. Experts estimate that by 2028, the size of the European market will be valued at 55,2 billion Euros.

To that end we are pushing to establish strategic relationships with relevant players in the Canadian cannabis industry and support them in the EU-GMP-Application process. 

Download our company presentation below:
Company Presentation

Farmako is unique

Biggest EU Investment

Farmako received a seven-digit investment from Heartbeat Labs. This is the most significant non-Canadian investment in Europe to date. This highlights that Europe is catching up to North American markets.

Focus on R&D

In the future, cannabis flowers will become a commodity. We prepare by investing heavily in research and development to offer our partners an edge over the competition.

Gateway to Europe

We pursue operations in all European markets with a legal basis for pharmaceutical cannabis.  We will be the first and most active to offer a truly European sales network.

Europe is getting started

European markets today are where some US and Canadian markets were a few years ago: Opening up their health care systems to cannabinoid therapies. In a few years, Europe will be home to the biggest number of patients worldwide. The market for pharmaceutical cannabis will the Europa’s fastest-growing industry over the next decade. We aim to be active in every country that initiates this change.

million people

in Europe are waiting for new treatments and improved natural drugs.

billion €

Total healthcare expenditure in European Union Member States alone.

billion €

is the estimated market size for pharmaceutical cannabis in Europe by 2028.

Have a question?